Table 2.
Clinical and Angiographic Characteristics Stratified by BMI
| Variable | BMI, kg/m2 | P Value | |||
|---|---|---|---|---|---|
| <20 (n=193) | 20–25 (n=1775) | 25–30 (n=3644) | >30 (n=3754) | ||
| Demographics and risk factors | |||||
| Age, y, mean (SD) | 79.5 (7.8) | 77.7 (7.0) | 75.9 (6.5) | 74.4 (6.1) | <0.001 |
| Male, n (%) | 68 (35) | 1001 (56) | 2650 (73) | 2483 (66) | <0.001 |
| BMI, mean (SD) | 18.7 (1.1) | 23.2 (1.3) | 27.5 (1.4) | 34.5 (4.2) | <0.001 |
| MI <24 hours, n (%) | 45 (24) | 376 (21) | 574 (16) | 505 (14) | <0.001 |
| Preprocedural shock, n (%) | 14 (7) | 98 (6) | 129 (4) | 92 (2) | <0.001 |
| Canadian Heart Class (III, IV, V), n (%) | 95 (49) | 894 (50) | 1975 (54) | 2178 (58) | <0.001 |
| Diabetes mellitus, n (%) | 26 (13) | 321 (18) | 866 (24) | 1603 (43) | <0.001 |
| Hypertension, n (%) | 157 (83) | 1338 (78) | 2889 (81) | 3287 (90) | <0.001 |
| History of cholesterol ≥240, n (%) | 131 (73) | 1356 (82) | 2963 (87) | 3218 (90) | <0.001 |
| Current smokers, n (%) | 29 (15) | 158 (9) | 220 (6) | 172 (5) | 0.008 |
| History of MI (>7 days), n (%) | 69 (37) | 575 (33) | 1206 (34) | 1333 (36) | 0.034 |
| Prior PTCA, n (%) | 59 (31) | 602 (34) | 1387 (38) | 1545 (41) | <0.001 |
| Prior CABG, n (%) | 33 (17) | 455 (26) | 1091 (30) | 1148 (31) | <0.001 |
| Peripheral vascular disease, n (%) | 42 (22) | 278 (16) | 534 (15) | 579 (16) | 0.08 |
| CVA/TIA, n (%) | 52 (27) | 291 (17) | 602 (17) | 570 (15) | <0.001 |
| Moderate or severe renal disease, n (%) | 14 (7) | 81 (5) | 145 (4) | 158 (4) | 0.15 |
| COPD, n (%) | 50 (26) | 280 (16) | 494 (14) | 532 (15) | <0.001 |
| Peptic ulcer disease, n (%) | 23 (12) | 129 (8) | 273 (8) | 278 (8) | 0.17 |
| Tumor, lymphoma, or leukemia, n (%) | 39 (20) | 342 (20) | 672 (19) | 620 (17) | 0.028 |
| Metastatic cancer, n (%) | 3 (2) | 26 (1) | 49 (1) | 44 (1) | 0.80 |
| Cardiac arrest before procedure, n (%) | 0 (0) | 5 (0) | 5 (0) | 3 (0) | 0.28 |
| LVEF ≤40%, n (%) | 41 (21) | 280 (16) | 465 (13) | 425 (11) | <0.001 |
| Procedural characteristics | |||||
| Multivessel disease, n (%) | 127 (71) | 1189 (71) | 2400 (69) | 2467 (70) | 0.83 |
| Type C lesion, n (%) | 100 (56) | 893 (54) | 1808 (52) | 1852 (52) | 0.41 |
| Thrombus, n (%) | 49 (28) | 455 (27) | 790 (23) | 768 (22) | <0.001 |
| TIMI 0–1 before procedure in any lesion, n (%) | 35 (23) | 297 (21) | 504 (18) | 500 (17) | 0.002 |
| PCI, n (%) | <0.001 | ||||
| Elective | 50 (26) | 553 (31) | 1323 (36) | 1378 (37) | |
| Urgent | 96 (50) | 849 (48) | 1767 (49) | 1890 (50) | |
| Emergency | 47 (24) | 373 (21) | 552 (15) | 485 (13) | |
| Use of drug‐eluting stents, n (%) | 88 (46) | 837 (47) | 1857 (51) | 2009 (54) | <0.001 |
| TIMI 3 after procedure in all lesions, n (%) | 175 (96) | 1604 (95) | 3334 (95) | 3376 (94) | 0.07 |
| Prophylactic intra‐aortic balloon pump, n (%) | 8 (4) | 48 (3) | 65 (2) | 54 (1) | 0.001 |
| Discharge medications | |||||
| Aspirin at discharge, n (%) | 179 (95) | 1658 (95) | 3456 (95) | 3601 (97) | 0.08 |
| Beta blocker at discharge, n (%) | 160 (85) | 1422 (81) | 3023 (83) | 3186 (85) | 0.006 |
| Lipid lowering agent at discharge, n (%) | 77 (41) | 859 (49) | 1931 (53) | 1932 (52) | 0.002 |
| Clopidogrel at discharge n (%) | 180 (93) | 1649 (93) | 3440 (94) | 3545 (94) | 0.30 |
| In‐hospital outcomes | |||||
| In‐hospital death, n (%) | 7 (4) | 50 (3) | 58 (2) | 50 (1) | <0.001 |
| In‐hospital any MI, n (%) | 13 (7) | 101 (6) | 169 (5) | 177 (5) | 0.21 |
BMI indicates body mass index; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; TIA, transient ischemic attack; TIMI, Thrombolysis in Myocardial Infarction.